Janssen Pharmaceuticals Inc.

12/03/2021 | Press release | Distributed by Public on 12/03/2021 09:40

Latest Phase 3 Data for First-in-Class TREMFYA® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.